Woodline Partners LP Reports New 7.0% Stake in OKYO Pharma LTD

Woodline Partners LP has filed a Schedule 13G disclosing a new 7.0% ownership stake in OKYO Pharma LTD. As of March 31, 2026, the reporting person beneficially owns 3,652,190 ordinary shares. Woodline Partners LP, a Delaware limited partnership, serves as the investment adviser to Woodline Master Fund LP, which directly holds the shares. The calculation of the ownership percentage is based on an aggregate of 52,479,257 ordinary shares outstanding, accounting for recent share issuances in February and March 2026, including shares from a prospectus offering and the partial exercise of an underwriters' option. The filing indicates that the securities were acquired in the ordinary course of business and are not held for the purpose of changing or influencing the control of the issuer. This filing marks a significant new position for Woodline Partners LP in the pharmaceutical company, crossing the 5% disclosure threshold.